Fosun was founded in 1992. After more than 30 years of development, Fosun has become a global innovation-driven consumer group. Adhering to the mission of creating happier lives for families worldwide, Fosun is committed to creating a global happiness ecosystem fulfilling the needs of families worldwide in Health, Happiness, and Wealth. In 2007, Fosun International was listed on the main board of the Hong Kong Stock Exchange (stock code: 00656.HK). As of 31 December 2024, Fosun International’s total assets amounted to RMB796.5 billion and it received an AA MSCI ESG rating.

Rooted in China, Fosun has been developing globally while remaining committed to its two core drivers of “globalization” and “innovation”. Fosun is one of the few Chinese companies that is equipped with global operational and investment capabilities, and has built strong capabilities in technology and innovation. After more than a decade of dedicated effort, Fosun has steadily established a global business presence, focusing on and continuing to deepen in the household consumption industry.

The globalization journey of Fosun began with the listing of Fosun International in Hong Kong. After 17 years since its listing, Fosun has established a business presence in more than 35 countries and regions around the world. In 2024, Fosun’s overseas revenue accounted for 49.3% of its total revenue. Since 2022, the model of “global organization + local operations” has become more mature, and Fosun’s competitive advantages in global research and development (R&D), product innovation, supply chain system, sales network, and ecosystem synergy have become more significant. For Fosun, globalization means more than just “two-way engagement” between the global and Chinese markets. It extends to the endogenous development of its ecosystem enterprises both domestically and internationally, encouraging them to actively expand their businesses beyond their home markets. Fosun adheres to the concept of “combining global growth momentum with global resources”, and has entered a stage of profound global operations, focusing on developing capabilities for global resource integration, global expansion, and localization.

Innovation serves as another core driver for Fosun’s development. Fosun has established a global innovation system integrating “independent R&D + investment incubation + ecosystem collaboration”. In 2024, Fosun’s investment in technology innovation amounted to approximately RMB6.9 billion. It has established more than 20 global technology innovation centers, covering various industries and fields, continuously fostering the launch of new technologies and products. For many years, Fosun has been dedicated to leveraging innovative technologies in product iteration, the R&D of blockbuster products, customer service, and customer engagement, and has cooperated with governments at various levels, universities, and scientific research institutes to maintain cutting-edge competitiveness through in-depth integration of industry, academic and research sectors. In 2024, Fosun launched the PharmAID decision intelligence platform, harnessing AI technology to accelerate and improve drug R&D. 

With over 30 years of extensive industrial operational experience, and leveraging its strengths in innovation and globalization, Fosun has collaborated with various partners to develop strategically advantageous industries and create high-quality projects. In March 2024, Fosun Pharma together with the Shenzhen Guidance Fund and other investors established a RMB5.0 billion biopharmaceutical industry fund to jointly promote the high-quality development of the pharmaceutical and healthcare industry in the Greater Bay Area. In June 2024, the Taicang Alps Resort Phase II project, which is funded by the Taicang Municipal Government and managed by Fosun Tourism Group (“FTG”) under an asset-light operating model, was signed. In December 2024, FTG signed an asset-light operation agreement for the Jinsha Bay project in Dapeng New District, Shenzhen, marking the launch of the first Club Med in the Greater Bay Area.

For over 30 years since its establishment, Fosun has consistently adhered to its corporate values of “Self-improvement, Teamwork, Performance, and Contribution to Society”. Fosun has diligently embraced its corporate social responsibility, achieving outstanding performance in environmental, social, and governance (ESG) practices. Fosun International received an MSCI ESG rating of AA, ranked in the top 5% among global peers in S&P Global’s Corporate Sustainability Assessment (CSA), and was selected as the top 1% in S&P Global’s Sustainability Yearbook 2024 (China Edition) for its outstanding performance. Fosun Foundation carries out public welfare activities in the fields of emergency relief, rural revitalization, health promotion and poverty alleviation, youth entrepreneurship, education, and culture & art, etc., serving many countries and regions around the world. Since the launch of the Rural Doctors Program at the end of 2017, the program has covered 78 counties in 16 provinces, municipalities, and autonomous regions across the country, supporting 25,000 rural doctors and benefiting 3 million rural families. In 2024, the Rural Doctors Program was included in the “20 Cases of Private Sector’s Sustainable Development in China for 20 Years” Report of the United Nations Global Compact. In terms of global public health, as at the end of 2024, Fosun Pharma had supplied a cumulative total of over 400 million doses of Artesun® (artesunate for injection) globally, saving more than 80 million patients with severe malaria worldwide.